The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis

American Journal of Pathology

Volumn 175, Issue 2, 2009, Pages 661-667

  Li, Qing ^a,b   Nacion, Kristine ^a   Bu, Hong ^b   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; GAMMA INTERFERON; INTERLEUKIN 17; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NAFAMSTAT MESILATE;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; ATTENUATION; CELL ACTIVITY; CELL TRANSFER; CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; DEMYELINATION; DISEASE SEVERITY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; ENZYME SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

EID: 68449086571     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081093     Document Type: Article

References (34)

1. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747
2. Guo B, Chang EY, Cheng G: The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008, 118:1680-1690
3. Wolinsky JS: The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol 2006, 98:273-292
4. Morrissey SP, Le Page E, Edan G: Mitoxantrone in the treatment of multiple sclerosis. Int MSJ 2005, 12:74-87
5. Chaudhuri A: Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ 2006, 332:416-419
6. Owens T: Animal models for multiple sclerosis. Adv Neurol 2006, 98:77-89
7. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7
8. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988, 140:1506-1510
9. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM: IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008, 205:1535-1541
10. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573
11. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH: Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 2006, 107:2461-2469
12. Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA, Sacks SH, Zhou W: Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 2008, 111:2452-2461
13. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME: Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005, 201:1523-1530
14. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS: Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007, 179:5793-5802
15. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS: Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008, 112:1759-1766
16. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME: Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435
17. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160:1558-1578
18. Fujii S, Hitomi Y: New synthetic inhibitors of C1r. C1 esterase, thrombin, plasmin, kallikrein, and trypsin. Biochim Biophys Acta 1981, 661:342-345
19. Nakase H, Itani T, Mimura J, Kawasaki T, Komori H, Okazaki K, Chiba T: Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration. J Gastroenterol Hepatol 2001, 16:944-945
20. Takeda K, Matsuno S, Sunamura M, Kakugawa Y: Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996, 171:394-398
21. Kobayashi T, Terao T, Maki M, Ikenoue T: Diagnosis and management of acute obstetrical DIC. Semin Thromb Hemost 2001, 27:161-167
22. Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y: Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 2003, 59:458-462
23. Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S: Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation-a preliminary report. J Pediatr Surg 1997, 32:531-535
24. Lin F, Immormino RM, Shoham M, Medof ME: Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains. Arch Biochem Biophys 2001, 393:67-72
25. Linington C, Lassmann H, Morgan BP, Compston DA: Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol 1989, 79:78-85
26. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM: Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition. P-selectin expression, and cellular infiltrate in spinal cords. J Immunol 2002, 168:4293-4300
27. Morariu MA, Dalmasso AP: Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann Neurol 1978, 4:427-430
28. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP: Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994, 152:5477-5484
29. Davoust N, Nataf S, Reiman R, Holers MV, Campbell IL, Barnum SR: Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J Immunol 1999, 163:6551-6556
30. Hopken UE, Lu B, Gerard NP, Gerard C: The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 1996, 383:86 -89
31. Szalai AJ, Hu X, Adams JE, Barnum SR: Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol 2007, 44:3132-3136
32. Marsh JE, Farmer CK, Jurcevic S, Wang Y, Carroll MC, Sacks SH: The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 2001, 72:1310-1318
33. Kirschfink M: Targeting complement in therapy. Immunol Rev 2001, 180:177-189
34. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243